Trader consensus on Polymarket reflects an 84% implied probability of no new COVID-19 variant of concern (VOC) designated by WHO before 2027, driven by the absence of any VOC classification since Omicron in 2021 and robust global SARS-CoV-2 surveillance. Recent spread of the highly mutated BA.3.2 ("Cicada") lineage—detected in 23+ countries and 31 U.S. states via wastewater and clinical samples since late 2025—has not met WHO's strict VOC criteria, remaining a variant under monitoring (VUM) due to no demonstrated growth advantage, increased severity, or significant vaccine escape beyond baseline Omicron sublineages. Endemic circulation, annual vaccine updates targeting strains like JN.1 descendants, and low prevalence (under 1% of U.S. sequences) reinforce this positioning, though an unforeseen surge in hospitalizations could shift odds before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoSì
$233,436 Vol.
$233,436 Vol.
Sì
$233,436 Vol.
$233,436 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercato aperto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 84% implied probability of no new COVID-19 variant of concern (VOC) designated by WHO before 2027, driven by the absence of any VOC classification since Omicron in 2021 and robust global SARS-CoV-2 surveillance. Recent spread of the highly mutated BA.3.2 ("Cicada") lineage—detected in 23+ countries and 31 U.S. states via wastewater and clinical samples since late 2025—has not met WHO's strict VOC criteria, remaining a variant under monitoring (VUM) due to no demonstrated growth advantage, increased severity, or significant vaccine escape beyond baseline Omicron sublineages. Endemic circulation, annual vaccine updates targeting strains like JN.1 descendants, and low prevalence (under 1% of U.S. sequences) reinforce this positioning, though an unforeseen surge in hospitalizations could shift odds before year-end.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti